Novo Nordisk Discloses Insider Trading Activity
Ticker: NONOF · Form: 6-K · Filed: Feb 7, 2025 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulatory-filing
Related Tickers: NVO
TL;DR
Novo Nordisk board/execs traded shares, filing shows.
AI Summary
On February 7, 2025, Novo Nordisk A/S filed a Form 6-K to report transactions in its shares by board members, executives, and associated persons. This disclosure is made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Why It Matters
This filing provides transparency into the trading activities of key individuals within Novo Nordisk, which can offer insights into their confidence in the company's future performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of insider trading activity and does not indicate any new material risks for the company.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- Regulation No. 596/2014 (regulation) — Governing market abuse disclosures
FAQ
What type of transactions are being disclosed by Novo Nordisk?
The filing discloses data of transactions made in Novo Nordisk shares by the company's board members, executives, and their associated persons.
What regulation mandates these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When was this company announcement made?
The company announcement was made on February 7, 2025.
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Is Novo Nordisk filing a Form 20-F or 40-F for its annual reports?
Novo Nordisk indicates it files annual reports under cover of Form 20-F.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2025-02-07 08:27:37
Filing Documents
- f6k_020725.htm (6-K) — 25KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-25-000689.txt ( ) — 165KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: February 7, 2025 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer